Review of Protocol. […***…]. Sage shall give due consideration and reasonably incorporate any input that CyDex provides regarding such protocol to the extent it pertains solely to the use and administration of Captisol. The contents of each such protocol shall be deemed to be Confidential Information of Sage, subject to the terms and provisions of Section 8 below.
Appears in 3 contracts
Samples: Commercial License Agreement (Sage Therapeutics, Inc.), Commercial License Agreement (Sage Therapeutics, Inc.), Commercial License Agreement (Sage Therapeutics, Inc.)
Review of Protocol. […***…]Sage shall provide information regarding each protocol for each Study and agrees to allow CyDex to review and comment upon the aspects of such protocol which pertain solely to the use and administration of Captisol. Sage shall give due consideration and reasonably incorporate any input that CyDex provides regarding such protocol to the extent it pertains solely to the use and administration of Captisol. The contents of each such protocol shall be deemed to be Confidential Information of Sage, subject to the terms and provisions of Section 8 below.
Appears in 1 contract
Samples: Commercial License Agreement (Ligand Pharmaceuticals Inc)
